Barr Pharma Deal Should Close - Analyst Blog
Barr Pharmaceuticals, Inc. (
BRL) is a global specialty pharmaceutical company engaged in the development, manufacture and marketing of branded and generic drugs. On July 18, 2008, Barr announced that it has entered into an agreement with
Teva Pharmaceuticals (
TEVA) whereby the latter will acquire Barr for $7.46 billion plus the assumption of net debt of approximately $1.5 billion.
We had issued a Sell rating on Barr after the company posted disappointing first-quarter results and slashed its full-year outlook. However, we moved back to a Hold rating following the Teva takeover announcement. This offer has come at the right time for Barr -- the deal should close later this year. We maintain a Hold rating with a $65 price target.
Barr markets and sells generic pharmaceutical products in the U.S., Europe and certain other countries in the rest of the world. Its generic product portfolio includes solid oral dosage forms, injectables, and cream/ointment products. Meanwhile, the branded product portfolio is mainly focused in the area of female healthcare.
The above story is the opinion of the author only and it does not reflect
iStockAnalyst opinion. Further, the author is not personally advising you
regarding the suitability of the story for your investment needs. In no event
iStockAnalyst will be liable for any loss or damage including without
limitation, indirect or consequential loss or damage, or any loss or damage
whatsoever arising from or arising out of, or in connection with the use of this
information. Please consult your investment advisor before making any investment
decision.
